Kamada Ltd.
HealthcareNASDAQ:KMDA · NASDAQ Global Select
+$0.00 today
Vol 0.03M · Avg 0.06M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
7.5%
avg 3.8%
ROIC
6.8%
avg 4.1%
ROA
5.3%
avg 3.2%
Analysis
ROE is currently the strongest return metric at 7.5% versus its period average of 3.8%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Amir London | Chief Executive Officer | $714,000.00 | — | 57 | $0.00 | <0.01% |
Chaime Orlev | Chief Financial Officer | $506,000.00 | — | 56 | $0.00 | <0.01% |
Eran Nir | Chief Operating Officer | $468,000.00 | — | 53 | $0.00 | <0.01% |
Boris Gorelik | Vice President of Business Development & Strategic Programs | $422,000.00 | — | 44 | $0.00 | <0.01% |
Jon R. Knight | Vice President of US Commercial Operations | $308,000.00 | — | 60 | $0.00 | <0.01% |
David Tsur | Co-Founder & Independent Deputy Chairman of the Board | $252,000.00 | — | 76 | $0.00 | <0.01% |
Nir Livneh | Vice President, General Counsel & Corporate Secretary | — | — | 47 | $0.00 | <0.01% |
Hanni Neheman | Vice President of Marketing & Sales | — | — | 56 | $0.00 | <0.01% |
Liron Reshef | Vice President of Human Resources | — | — | 54 | $0.00 | <0.01% |
Shavit Beladev | Vice President of Kamada Plasma | — | — | 55 | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -1.2% | +9.7% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -1.2% over three years. Forward estimates point to Revenue at +9.7% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Tactile Systems Technology, Inc.
NASDAQ:TCMD
$593.46M
Solid Biosciences Inc.
NASDAQ:SLDB
$556.28M
XOMA Royalty Corp.
NASDAQ:XOMA
$524.09M
Evolus, Inc.
NASDAQ:EOLS
$443.20M
PureTech Health plc
NASDAQ:PRTC
$424.07M
Auna S.A.
NYSE:AUNA
$364.93M
Semler Scientific, Inc.
SMLR
$310.75M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$300.28M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Galectin Therapeutics Inc.
NASDAQ:GALT
$175.84M
Who manages KMDA?
Kamada Ltd. (KMDA) lists 10 active executives. The top listed executive is Boris Gorelik, Vice President of Business Development & Strategic Programs.
Are KMDA insiders buying or selling?
Recent insider activity shows net selling of $141,933.75.
Explore More
Continue the stock analysis
Jump to another research area for this company.